Macrophages target tumor cells following monoclonal antibody therapy

January 16, 2014

Monoclonal antibodies directed against tumor antigens have proven effective for treating some forms of cancer. Despite the increasing use of monoclonal antibody therapy, it is not clear how these antibodies drive tumor removal.

In this issue of the Journal of Clinical Investigation, Marjolein van Egmond and colleagues at the VU University Medical Center found that macrophage populations mediate tumor cell removal following monoclonal antibody treatment by actively phagocytosing tumor cells. Macrophage-dependent tumor cell removal required both the high affinity and low affinity Fc receptors.

This study suggests that monoclonal antibody therapies that are optimized to enhance macrophage recruitment and activity may enhance removal of circulating in cancer patients.

Explore further: Bright future ahead for antibody cancer therapy

More information: Macrophages eliminate circulating tumor cells after monoclonal antibody therapy, J Clin Invest. DOI: 10.1172/JCI66776

Related Stories

Bright future ahead for antibody cancer therapy

March 15, 2012

Antibodies, once touted as the "magic bullets" of cancer care, are now fulfilling that promise and more advances are on the way, say cancer researchers at the Georgetown Lombardi Comprehensive Cancer Center

Monoclonal antibody targets, kills leukemia cells

March 25, 2013

Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells.

Monoclonal antibodies show promise as effective HIV therapy

October 30, 2013

A research team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) has demonstrated that a group of recently discovered antibodies may be a highly effective therapy for the treatment of HIV. Published on-line ...

Engineered anti-toxin antibodies improve efficacy

January 9, 2014

The effectiveness of toxin-neutralizing antibodies is considered to be mediated through the interaction of the variable region of the antibody and the toxin; however, recent studies suggest that the constant region (Fc) of ...

Recommended for you

Combination therapy can prevent cytostatic resistance

November 26, 2015

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...

Forecasting the path of breast cancer in a patient

November 23, 2015

USC researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting and surfing the Web.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.